Search research articles
Contact Us
Filters
Showing results (271-280 of 313) with videos related to
Page
of 32
Sort By:
Nature Cell Biology
|
March 16, 2022
Temporal and spatial topography of cell proliferation in cancer
Giorgio Gaglia, Sheheryar Kabraji, Danae Rammos, et al.
Journal of Pediatric Surgery
|
July 13, 2010
Endorectal pull-through for Hirschsprung's disease-a multicenter, long-term comparison of results: transanal vs transabdominal approach
Anne C Kim, Jacob C Langer, Aimee C Pastor, et al.
Cancer Cell
|
August 14, 2014
Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor
Gang Lu, Qing Zhang, Ying Huang, et al.
Cancer Cell
|
March 16, 2016
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
Shom Goel, Qi Wang, April C Watt, et al.
Nature
|
September 18, 2012
Cross-neutralization of influenza A viruses mediated by a single antibody loop
Damian C Ekiert, Arun K Kashyap, John Steel, et al.
Cancer Immunology Research
|
April 21, 2022
Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer
Carlos R Gil Del Alcazar, Anne Trinh, Maša Alečković, et al.
ESMO Open
|
July 27, 2025
Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study
C Corti, X Chu, P Exman, et al.
Nature Communications
|
May 31, 2022
STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer
Qiwei Wang, Johann S Bergholz, Liya Ding, et al.
Developmental Cell
|
May 26, 2022
A human breast atlas integrating single-cell proteomics and transcriptomics
G Kenneth Gray, Carman Man-Chung Li, Jennifer M Rosenbluth, et al.
ESMO Open
|
March 11, 2026
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer
S Jacob, E L Mayer, N Kacik, et al.
Page
of 32
Search research articles
Search
Showing results (271-280 of 313) with videos related to
Sort By:
Page
of 32
Nature Cell Biology
|
March 16, 2022
Temporal and spatial topography of cell proliferation in cancer
Giorgio Gaglia, Sheheryar Kabraji, Danae Rammos, et al.
Journal of Pediatric Surgery
|
July 13, 2010
Endorectal pull-through for Hirschsprung's disease-a multicenter, long-term comparison of results: transanal vs transabdominal approach
Anne C Kim, Jacob C Langer, Aimee C Pastor, et al.
Cancer Cell
|
August 14, 2014
Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor
Gang Lu, Qing Zhang, Ying Huang, et al.
Cancer Cell
|
March 16, 2016
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
Shom Goel, Qi Wang, April C Watt, et al.
Nature
|
September 18, 2012
Cross-neutralization of influenza A viruses mediated by a single antibody loop
Damian C Ekiert, Arun K Kashyap, John Steel, et al.
Cancer Immunology Research
|
April 21, 2022
Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer
Carlos R Gil Del Alcazar, Anne Trinh, Maša Alečković, et al.
ESMO Open
|
July 27, 2025
Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study
C Corti, X Chu, P Exman, et al.
Nature Communications
|
May 31, 2022
STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer
Qiwei Wang, Johann S Bergholz, Liya Ding, et al.
Developmental Cell
|
May 26, 2022
A human breast atlas integrating single-cell proteomics and transcriptomics
G Kenneth Gray, Carman Man-Chung Li, Jennifer M Rosenbluth, et al.
ESMO Open
|
March 11, 2026
TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer
S Jacob, E L Mayer, N Kacik, et al.
Page
of 32